Boundless Bio, Inc.(BOLD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BOLD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Boundless Bio, Inc. (BOLD), a Healthcare sector company. BOLD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Boundless Bio, Inc. reports net income of $-23.7M, free cash flow of $-21.0M. Top institutional holders of BOLD by reported 13-F value include ARCH Venture Management, FMR, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. BOLD trades on the Nasdaq exchange and files with the SEC under CIK 1782303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Boundless Bio, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-23.7M
Free Cash Flow
Q2 2026
$-21.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+11.0% YoYOperating Income
+13.3% YoYEPS (Diluted)
+32.5% YoYTotal Assets
-23.9% YoYOp. Cash Flow
+23.3% YoYFree Cash Flow
+25.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-58.2M +11.0% | $-65.4M -32.2% | $-49.4M | — |
| Operating Income | $-63.6M +13.3% | $-73.3M -33.7% | $-54.8M | — |
| EPS (Diluted) | $-2.60 +32.5% | $-3.85 +90.5% | $-40.65 | — |
| Total Assets | $157.1M -23.9% | $206.4M +58.9% | $129.9M | — |
| Operating Cash Flow | $-46.7M +23.3% | $-60.8M -29.8% | $-46.9M | — |
| Free Cash Flow | $-47.2M +25.5% | $-63.4M -33.5% | $-47.5M | — |
Get alerted when BOLD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Boundless Bio, Inc. including:
Top Institutional Holders of BOLD
ARCH Venture Management, LLC
$6.7M2,694,095 shFMR LLC
$6.5M2,581,055 shTANG CAPITAL MANAGEMENT LLC
$6.4M2,559,875 shADAR1 Capital Management, LLC
$4.9M1,968,216 shCormorant Asset Management, LP
$2.5M1,000,000 shVANGUARD CAPITAL MANAGEMENT LLC
$1.5M614,923 shWELLINGTON MANAGEMENT GROUP LLP
$1.4M556,233 shMILLENNIUM MANAGEMENT LLC
$1.2M478,639 shRENAISSANCE TECHNOLOGIES LLC
$1.2M471,570 shAlyeska Investment Group, L.P.
$750.0K300,000 sh
| Fund | Value | Shares |
|---|---|---|
| ARCH Venture Management, LLC | $6.7M | 2,694,095 |
| FMR LLC | $6.5M | 2,581,055 |
| TANG CAPITAL MANAGEMENT LLC | $6.4M | 2,559,875 |
| ADAR1 Capital Management, LLC | $4.9M | 1,968,216 |
| Cormorant Asset Management, LP | $2.5M | 1,000,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.5M | 614,923 |
| WELLINGTON MANAGEMENT GROUP LLP | $1.4M | 556,233 |
| MILLENNIUM MANAGEMENT LLC | $1.2M | 478,639 |
| RENAISSANCE TECHNOLOGIES LLC | $1.2M | 471,570 |
| Alyeska Investment Group, L.P. | $750.0K | 300,000 |
More Healthcare Companies
View all Healthcare →Put BOLD on your watchlist
Track score changes the day Boundless Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BOLD a good stock to buy?
13F Pro's AI-powered analysis of Boundless Bio, Inc. (BOLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BOLD are available on the BOLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BOLD is classified as a small company.
Which hedge funds own BOLD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BOLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Boundless Bio, Inc.'s investment landscape.